ImmunityBio, Inc. is an innovative immunotherapy company at the forefront of developing groundbreaking treatments that harness the potential of memory T-cells to address various cancer types. The company's proprietary cancer vaccine represents a significant advancement in oncology, aiming to enhance therapeutic effectiveness while minimizing the need for conventional high-dose chemotherapy. With a strong biotechnology platform and a commitment to redefining cancer treatment, ImmunityBio is well-positioned to lead in the rapidly evolving landscape of cancer therapeutics, ultimately striving to improve patient outcomes and quality of life. Show more

Location: 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, UNITED STATES, 92121, San Diego, CA, 92121, USA | Website: https://immunitybio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE


Market Cap

6.156B

52 Wk Range

$1.83 - $8.28

Previous Close

$5.91

Open

$5.78

Volume

29,537,843

Day Range

$5.67 - $6.46

Enterprise Value

6.76B

Cash

60.24M

Avg Qtr Burn

-68.91M

Insider Ownership

66.41%

Institutional Own.

15.46%

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Anktiva (N-803) + BCG Details
Non-muscle invasive bladder cancer

Approved

Update

Phase 3

Initiation

PD-L1 t-haNK Details
Pancreatic cancer

Phase 2/3

Update

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

ANKTIVA Details
Lymphopenia

Phase 2

Update

Phase 1/2

Initiation

CAR-NK / CD19 t-haNK Details
Non-Hodgkin lymphoma

Phase 1

Update

N-803 (Anktiva), haNK and Avelumab Details
Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer

Failed

Discontinued

hAd5-COVID-19 Details
Vaccine, COVID-19

Failed

Discontinued